COVID‐19–associated pulmonary aspergillosis: a prospective single‐center dual case series

<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>COVID‐19–associated pulmonary aspergillosis (CAPA) has emerged as an invasive fungal disease, often affecting previously immunocompetent, mechanically ventilated, intensive care unit (ICU) patients. Incidence rates of 3.8%–33.3% have been reported depending on the geographic area, with high (47%) mortality.</jats:p></jats:sec><jats:sec><jats:title>Objectives</jats:title><jats:p>Here, we describe a single‐centre prospective case series with CAPA cases from both the first (March‐May, <jats:italic>n</jats:italic> = 5/33) and second (mid‐September through mid‐December, <jats:italic>n</jats:italic> = 8/33) COVID‐19 wave at a 500‐bed teaching hospital in the Netherlands.</jats:p></jats:sec><jats:sec><jats:title>Patients/Methods</jats:title><jats:p>In the first COVID‐19 wave, a total of 265 SARS‐CoV‐2 PCR‐positive patients were admitted to our hospital of whom 33 needed intubation and mechanical ventilation. In the second wave, 508 SARS‐CoV‐2 PCR‐positive patients were admitted of whom 33 needed mechanical ventilation. Data were prospectively collected.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>We found a significant decrease in COVID‐19 patients needing mechanical ventilation in the ICU in the second wave (<jats:italic>p</jats:italic> < .01). From these patients, however, a higher percentage were diagnosed with CAPA (24.2% vs 15.2%), although not significant (<jats:italic>p</jats:italic> = .36). All CAPA patients encountered in the second wave received dexamethasone. Mortality between both groups was similarly high (40%–50%). Moreover, we found environmental TR<jats:sub>34</jats:sub>/L98H azole‐resistant <jats:italic>Aspergillus fumigatus</jats:italic> isolates in two separate patients.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>In this series, 19.7% (<jats:italic>n</jats:italic> = 13/66) of mechanically ventilated SARS‐CoV‐2 patients were diagnosed with CAPA. In addition, we found a significant reduction in COVID‐19 patients needing mechanical ventilation on the ICU in the second wave. Numbers are too small to determine whether there is a true difference in CAPA incidence in mechanically ventilated patients between the two waves, and whether it could be attributed to dexamethasone SARS‐CoV‐2 therapy.</jats:p></jats:sec>